News
AbbVie and Neomorph to develop molecular glue degraders for oncology and immunology
AbbVie and Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Molecular glue...
Viralgen and Axovia to manufacture investigational gene therapy for retinal dystrophy in Bardet-Biedl Syndrome...
Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy...
Zai Lab receives U.S. FDA Orphan Drug Designation for small cell lung cancer treatment
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Zai Lab's ZL-1310, a potential highly active first-in-class DLL3 antibody-drug...
